The company reported earnings per share of $1.17 for the third quarter ended Oct. 31, 2020, compared to a loss per share of $0.91 for the quarter ended Nov. 2, 2019. Third quarter operating income was $580.6 million compared to an operating loss of $151.2 million last year, and net income was $330.6 million compared to a net loss of $252.0 million last year.
details at: http://investors.lb.com/news-releases/news-release-details/l-brands-reports-record-third-quarter-2020-results
Related Posts
Macy's, Inc. announced an accelerated expansion of its small-format store strategy, potentially tripling the total number of its small-format stores through fall 2025. Beginning in 2024, up to 30 new Macy’s small-format locations will open across the country. This expansion is in addition to the nearly 15 small-format Macy’s and Bloomie’s locations that Macy’s, Inc. currently operates. Paired with a premier digital experience, these small-format stores enhance the company’s store portfolio with a mix of the best on- and off-mall locations, to deliver a seamless shopping experience across channels.
Dear Colleagues, I am writing today because, as you may have heard, Paramount has terminated its agreement to sell Simon & Schuster to Penguin Random House, and there will be no appeal of Judge Florence Pan’s decision to block the merger of the two companies. This news is still fresh, and at this point I have no specific information to impart about what will happen in the coming months. You may read or hear rumors and speculation about our future, but you can be assured that I will keep you informed as soon as there is pertinent news I can share. I am grateful for your patience and dedication to our mission during all that has transpired over these many months since the sale began. Ultimately, what matters the most is the work we do together, on behalf of our authors and our books. Over the past three years, we have reached new heights of accomplishment. Simon & Schuster has never been more profitable and valuable than it is today. And that is because of the effort, ingenuity, and perseverance that you bring to our endeavors.
Walgreens Boots Alliance, Inc. announces that it has entered into an agreement to reduce its stake in Guangzhou Pharmaceuticals Corporation, a pharmaceutical wholesaling joint venture in China, following an offer from its joint venture partner Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. Subject to regulatory review and approval and other customary closing conditions, Walgreens Boots Alliance will sell a 30% interest in Guangzhou Pharmaceuticals Corporation to Guangzhou Baiyunshan Pharmaceutical Holdings that, following the proposed sale, would own 80%. Upon completion, Walgreens Boots Alliance will own a 20% interest in Guangzhou Pharmaceuticals Corporation and will continue to account for its remaining stake as an equity method investment.